Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
850 participants
High
Withdrawals due to adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in withdrawals due to adverse events Due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.75 [0.46, 1.21]
1165 participants
High
BASDAI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
190 participants
Moderate
BASFI Scale from 0 to 100 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
1 finding from 1 review
no estimate extracted
356 participants
High
BASMI Scale from 0 to 10 (higher is worse) · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Radiographic progression · patients with axSpA (AS and nr‐axSpA)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)
Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.69 [0.36, 7.97]
671 participants
Moderate
Physical function · patients with rheumatoid arthritis
1 finding from 1 review
Cardiovascular events (myocardial infarction, stroke) · patients with rheumatoid arthritis
Celecoxib showed no clear difference in cardiovascular events (myocardial infarction, stroke) compared with traditional NSAIDs (low certainty).
1 finding from 1 review
Incidence of gastroduodenal ulcers ≥ 3 mm · patients with rheumatoid arthritis
Celecoxib probably leads to lower incidence of gastroduodenal ulcers ≥ 3 mm compared with traditional NSAIDs (moderate certainty).
1 finding from 1 review
Short‐term serious adverse events · patients with rheumatoid arthritis
Celecoxib showed no clear difference in short‐term serious adverse events compared with traditional NSAIDs (low certainty).
1 finding from 1 review
Total number of withdrawals · patients with rheumatoid arthritis
Celecoxib probably leads to lower total withdrawals; compared with traditional NSAIDs (moderate certainty).
1 finding from 1 review
Clinical improvement: American College of Rheumatology 20% improvement criteria (ACR20) · patients with rheumatoid arthritis
Celecoxib showed no clear difference in clinical improvement: American College of Rheumatology 20%… compared with traditional NSAIDs (moderate certainty).
1 finding from 1 review
Pain A 0 t o 100 visual or numerical scale, where 0 equals no pain at all and 100 is the worst pain imaginable · patients with rheumatoid arthritis
1 finding from 1 review